Compare Booz Allen Hamilton Holding Corporation (BAH) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Illumina, Inc. — how do they compare? Booz Allen Hamilton Holding Corporation trades at $77.21 (market cap $9.45B), while Illumina, Inc. trades at $190.07 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 3.1× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BAH | ILMN | |
|---|---|---|
Market Cap | $9.45B | $29.12B |
Sector | Industrials | Health |
52-Week High | $111.63 | $205.10 |
52-Week Low | $59.71 | $91.00 |
Enterprise Value | $13.07B | $30.48B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.9, up 2.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 7.01% net margin and 68.11% ROE, supported by $11.98B revenue in 2025. Analysts maintain a Buy consensus with a $84.67 price target, citing government contracts and AI investments as growth drivers, though debt levels and civil revenue weakness pose concerns.
The outlook for BAH is positive due to consistent earnings outperformance and strategic focus on national security and cybersecurity. Investment appeal lies in its discounted valuation (P/E 12.33) and dividend yield, but risks include high leverage (debt-to-asset 54.67%) and reliance on government spending, which could impact growth if budget pressures arise.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
